Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Established diagnosis of Ulcerative Colitis (UC)~* Moderately to severely active left sided UC assessed by central reading~* Current oral 5-Aminosalicylic Acid (5-ASA)/ Sulphasalazine (SP) use or a history of oral 5-ASA/SP use~* Current Glucocorticosteroids (GCS) use or history of GCS dependency, refractory, or intolerance~* Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following agents:~  * Immunomodulators~ * Tumor Necrosis Factor alpha (TNF-α) inhibitors and/or anti-integrins~Exclusion Criteria:~* Suspicion of differential diagnosis~* Acute fulminant UC and/or signs of systemic toxicity~* UC limited to the rectum (disease which extend \<15 cm above the anal verge)~* History of malignancy~* History or presence of any clinically significant disorder~* Concomitant treatment with cyclosporine, methotrexate, tacrolimus, TNF-α inhibitors, anti-integrins or similar immunosuppressants and immunomodulators~* Treatment with rectal GCS, 5-ASA/SP or tacrolimus~* Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs)~* Serious active infection~* Gastrointestinal infections~* Currently receiving parenteral nutrition or blood transfusions~* Females who are lactating or have a positive serum pregnancy test~* Women of childbearing potential not using reliable contraceptive methods~* Concurrent participation in another clinical study~* Previous exposure to cobitolimod

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cobitolimod Dose 2x31 mg (Type: EXPERIMENTAL): Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
- Cobitolimod Dose 2x125 mg (Type: EXPERIMENTAL): Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
- Cobitolimod Dose 2x250 mg (Type: EXPERIMENTAL): Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
- Cobitolimod Dose 4x125 mg (Type: EXPERIMENTAL): Dose 125 mg of cobitolimod, at 4 occasions
- Placebo (Type: PLACEBO_COMPARATOR): Placebo at four occasions

Based on this trial design, predict the completion outcome and termination type (if applicable).